Home
Search results “Leuprolide for prostate cancer”
Hormone Therapy Side Effects
 
01:48
Edward Weber, M.D. Medical Oncologist, describes the side effects of cardiac complications when receiving Androgen Deprivation Therapy, ADT, also known as Hormone Therapy, for treatment of Prostate Cancer. ADT is used to reduce the production of testosterone needed for the growth of prostate cancer cells. But ADT can have cardiac complications, especially on men with a history of heart disease. Video Development: Dean Dubinsky Video Transcript: Prostate Cancer Free Foundation. Increasing Knowledge - Building Hope. Edward Weber, M.D. Medical Oncologist, Prostate Cancer Results Study Group. Men with prostate cancer are much more likely to die of cardiac disease and not from prostate cancer, unless the diagnosis is made at a very late stage.  For that reason, a man’s cardiac history, his cardiovascular risk factors, and the choice of which drug to use for ADT are very critical issues. Androgen deprivation therapy, ADT, the  mainstay of treatment for years, is associated with a 10-20% increased risk of cardiac complications, such as a heart attack, stroke, or sudden death. If a man has already had two important cardiac events before starting ADT the risk of another cardiac event is greatly increased. Surprisingly these serious problems can occur within the  first 6 - 12 months. Degarelix (Firmagon), the newer drug for ADT, is less toxic to the heart than leuprolide (Lupron), and, for many clinicians, is becoming the preferred agent for hormone therapy. Every man before starting ADT needs to have a thorough evaluation for cardiac risk factors. This exam should focus on past history of cardiovascular disease, hypertension, diabetes, elevated cholesterol and triglycerides, and the life-style factors diet and exercise habits.   In some men this pre-ADT evaluation will lead to choosing Firmagon over Lupron, or receiving the shortest period of drug exposure as possible, or beginning a program for modification of cardiac risk factors — or possibly avoiding the use of these drugs entirely. Prostate Cancer Free Foundation https://prostatecancerfree.org
Prostate Cancer Hormone Side Effects
 
01:49
Edward Weber, M.D. Medical Oncologist, describes the side effects of cardiac complications when receiving Androgen Deprivation Therapy, ADT, also known as Hormone Therapy, for treatment of Prostate Cancer. Video Developer: Dean Dubinsky Website: ProstateCancerFree.org Transcript: Prostate Cancer Free Foundation. Increasing Knowledge – Building Hope. Edward Weber, M.D. Medical Oncologist, Prostate Cancer Results Study Group. Men with prostate cancer are much more likely to die of cardiac disease and not from prostate cancer, unless the diagnosis is made at a very late stage. For that reason, a man’s cardiac history, his cardiovascular risk factors, and the choice of which drug to use for ADT are very critical issues. Androgen deprivation therapy, ADT, the mainstay of treatment for years, is associated with a 10-20% increased risk of cardiac complications, such as a heart attack, stroke, or sudden death. If a man has already had two important cardiac events before starting ADT the risk of another cardiac event is greatly increased. Surprisingly these serious problems can occur within the first 6 – 12 months. Degarelix (Firmagon), the newer drug for ADT, is less toxic to the heart than leuprolide (Lupron), and, for many clinicians, is becoming the preferred agent for hormone therapy. Every man before starting ADT needs to have a thorough evaluation for cardiac risk factors. This exam should focus on past history of cardiovascular disease, hypertension, diabetes, elevated cholesterol and triglycerides, and the life-style factors diet and exercise habits. In some men this pre-ADT evaluation will lead to choosing Firmagon over Lupron, or receiving the shortest period of drug exposure as possible, or beginning a program for modification of cardiac risk factors — or possibly avoiding the use of these drugs entirely. Prostate Cancer Free Foundation. www.prostatecancerfree.org
Prostate Cancer Injections
 
02:05
Newly-approved prostate cancer ejections giving cancer patients more quality of life.
Dr. Andre Goy on Neoadjuvant Leuprolide and Abiraterone in High Risk Localized Prostate Cancer
 
01:35
Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses a phase II trial that combined leuprolide acetate with abiraterone acetate before prostatectomy in patients with localized high-risk prostate cancer. Read more at http://www.onclive.com/onclive-tv/Dr-Goy-on-Neoadjuvant-Hormonal-Therapy-Plus-Zytiga
Views: 419 OncLiveTV
Possible Side Effects of Prostate Cancer Treatment
 
04:39
Treatment options for prostate cancer can lead to a range of side effects. Dr. Arthur Burnett, Patrick C. Walsh Distinguished Professor of Urology, Director, Basic Science Laboratory in Neurourology and Director, Male Consultation Clinic at Johns Hopkins Medical Institutions discusses these possible side effects and how men and their family and caregivers can manage the impact of treatment.
Views: 3968 Genomic Health, Inc.
Neoadjuvant abiraterone acetate plus leuprolide acetate for localised high-risk prostate cancer
 
05:04
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa for patients with localised high-risk prostate cancer.
Benign Prostate Hyperplasia (BPH) and Prostate Cancer for USMLE Step 2
 
34:35
Benign Prostatic Hyperplasia (BPH) and Prostate Cancer epidemiology, etiliogy, causes and symptoms, investigations, treatment and management. Handwritten full lecture for USMLE. ANATOMY of PROSTATE Central zone of prostate sorrounds ejaculatory duct. The Transitional zone of prostate encompases meddle part of urethra. Peripheral zone is placed outside. Prostate cancer is most common in peripheral zone (60-70%). The Central zone is the second most common site for prostate cancer (25%). The Transition zone only has an occurence rate of 5% for prostate cancer. Benign Prostate Hyperplasia (BPH) is in the transition zone and that is why it presents mostly with urinary symptoms. BENIGN PROSTATIC HYPERPLASIA (BPH) Prostate is heavily influenced by DHT and testosterone, however, DHT is ten times more sensitive. Testosterone is converted to DHT by 5alpha reductase. This causes hyperplasia of collagen cells and the smooth muscle. The collagen will cause a physical obstruction while the smooth muscle will cause mechanical obstruction. Eventually there is bladder enlargement which may forma false diverticulum (outpouching of the bladder). Clinical Signs and Symptoms Obstructive symptoms - Consists of the patients experiencing hesitancy, difficulty voiding, straining, decrease in the force of stream and dribbling of urine. Irritation symptoms - increase frequency or urgency as well as nocturia. These symptoms occur as the bladder gets larger and begins to overflow. These symptoms can produce an International Prostate Symptoms Score (IPSS) which determines severity of Benign prostatic Hyperplasia through symptoms. Diagnosis of Benign Prostatic Hyperplasia Digital Rectum Exam is done initially, however it doesn't correlate well with symptoms and it is very difficult to palpate. Urinalysis is also done to rule out prostatitis. PSA is organ specific but can be elevated in cancer and prostatitis. Ultrasound or CT to look for complications such as bladder distention. Transrectal ultrasound is used before surgery. Treatment for Benign Prostatic Hyperplasia (BPH) If the degree of benign prostatic hyperplasia (BPH) is minimal such as 0-7 on the IPSS score than watchful waiting because most spontaneously. So for these patients continue monitoring PSA and Digital Rectums Exams. If getting worse continue to medical treatment. Alpha 1 blocker allows relaxation of the smooth muscle that may be constricting the urethra. Finasteride is a 5 alpha reductase inhibitor to prevent formation of DHT from testosterone and help debulk the prostate. Commonly used drugs are terazosin and doxazosin but this can lead to hypotension. More specific is an Alpha A1 blocker such as tamsolusin which is more specific for the prostate and therefore hypotension is not present but can lead to retrograde ejaculation. Surgery - If medical therapy doesn't work for the Benign Prostatic Hyperplasia (BPH). Two procedures transurethral and prostatectomy. PROSTATE CANCER CLINICAL SIGNS AND SYMPTOMS of PROSTATE CANCER Can range from asymptomatic to completely fatal. Screening - Digital Rectal Exam is not helpful and PSA is the only method being used. Local Disease causes symptoms similar to Benign Prostatic Hyperplasia symptoms, but this suggests involvement of the transition zone. Metastasis disease include symtpoms related to osteoblastic bone growth, primarily the spine leading to neurological symptoms and back pain. Prostatic Cancer patients may also have patients related to lower extremities due to lymphatic obstruction INVESTIGATION for PROSTATE CANCER Digital Rectal Exam shows a single nodule and correlates well with severity of disease. However, it may be a cyst or a stone. PSA normally should be less than 2.5ng/dL (some say less than 4 ng/dL). May also be helpful to measure as PSA Velocity and Free PSA versus Bound PSA. This helps distinguish Benign Prostatic Hyperplasia from Prostate Cancer. Transrectal Ultrasound may also be used. Biopsy uses the Gleasson Score which looks at the tissue of prostate under microscope and given a score out of 5. Staging of prostate cancer utilizes the TNM score. TREATMENT AND MANAGEMENT of PROSTATE CANCER Start with active surveillance by monitoring PSA/DRE/Biopsies. Radiation - Has a lot of GIT complications and may lead to erectile Dysfunction. Brachytherapy is the new treatment. Radical Prostatectomy - May lead to neruovascular damage causing Erectile Dysfunction and damage to urethra my lead to incontinence. After treatment continue to monitor PSA to look for Metastasis or resurgency of cancer. TREATMENT OF METASTASIS OF PROSTATE CANCER Castration - Orchiectomy (Gold Standard), Leuprolide/Ghrelin (GnRH) but these have a temporary increase in androgens, and Anti-Androgens (Flutamide). Castration Resistant Prostate Cancer (CRPC) are tumors that are still growing despite castration. Then use chemotherapy (Doxitexal, Mitoxantrone, Dosatinib)
Views: 31781 the study spot
Dr. Slovin on an Ongoing Study With Degarelix Leuprolide in Prostate Cancer
 
00:55
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
Views: 68 OncLiveTV
Firmagon V Lupron + PCa Remissions
 
04:45
Purchase a transcript here: https://rivanna-health-publications.myshopify.com
Views: 1099 ProstateForum
Common Prostate Cancer Therapy May Increase Dementia Risk HD
 
03:19
For men with prostate cancer, androgen deprivation therapy, or ADT, is a common course of treatment. The testosterone reducing therapy is first-line treatment for prostate cancer that has spread to stop its growth, but now a recent study has suggested that long term use of ADT is associated with an increased risk for dementia. Eric Klein, M.D., comments. NOTE: Members of the media may download broadcast quality video, audio, script and web assets for editorial use at newsroom.clevelandclinic.org. ➨ Visit Cleveland Clinic: http://bit.ly/XlxDfr ➨ Visit Health Essentials from Cleveland Clinic: http://bit.ly/VBQ3nW ➨ Subscribe to our YouTube Channel: http://bit.ly/W0bJ0y ➨ Like Cleveland Clinic on Facebook: http://on.fb.me/WMFkul ➨ Follow Cleveland Clinic on Twitter: http://bit.ly/Uua1Gs ➨ Follow Cleveland Clinic on Google+: http://bit.ly/136vcTe ➨ Follow Cleveland Clinic on Instagram: http://bit.ly/12gMABx ➨ Connect with Cleveland Clinic on LinkedIn: http://linkd.in/120XfNs ➨ Follow Cleveland Clinic on Pinterest: http://bit.ly/11QqS3A
Views: 121 Cleveland Clinic
Meet the expert - Paul, treated with ADT for prostate cancer
 
02:11
Paul found out that his PSA was 300 during his routine medical check-up in 2014. A subsequent bone scan showed spots all over his body and he has been on androgen deprivation therapy since then for seven months at the time of the video recording in October 2014. In his interview, he shares some tips for men considering androgen deprivation therapy. For more info visit http://ifiweretom.ubc.ca
Views: 159 If I Were Tom
Priority Reviews in Prostate and Bladder Cancer, NCCN CRC Guidelines Update, and More
 
10:25
Gina Columbus reports on a priority review designation in prostate cancer, a breakthrough therapy designation in bladder cancer, promising phase III findings in lung cancer, an addition to the NCCN Colorectal Cancer Guidelines, and a decision made by the CMS for genomic testing.
Views: 78 OncLiveTV
Dr. Mary-Ellen Taplin on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate
 
01:41
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, discusses a randomized phase II trial that provided abiraterone acetate (Zytiga) in combination with the hormonal therapy leuprolide acetate before prostatectomy for men with localized high-risk prostate cancer (LHRPC).
Views: 628 OncLiveTV
The Role of Abiraterone in Prostate Cancer
 
02:06
Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the role of abiraterone acetate (Zytiga) in the treatment of patients with prostate cancer, and the questions that remain about its use.
Views: 636 Targeted Oncology
Lupron side effects
 
09:28
6 days after first Lupron injection. Side effects and vitamins I am currently taking.
Views: 11471 Alexandria Marchak
Early Castration Resistance depends on Lupron Regimen .mp4
 
05:33
Early Castration Resistance depends on Lupron Regimen .mp4
Views: 689 DrBarken
Trial of LHRHa, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy
 
02:45
Eleni Efstathiou, MD, PhD of the University of Texas MD Anderson Cancer Center, Houston, Texas, TX, provides an overview of the Phase II trial of leuprolide acetate (LHRHa) and abiraterone acetate with or without ENZA (neoadjuvant enzalutamide) in high-risk prostate cancer (NCT01946165). Dr Efstathiou explains that the trial should not be considered as an independent trial, but as one in a series of companion trials. She explains that novel agents that are available from the more advanced disease settings, to explore what may be happening at a tumor micro-environment level, and treating patients and sampling their cancers. This was done in the metastatic castrate-resistant prostate cancer, looking at the bone micro-environment in the past years. She further discusses the presentation regarding the first trial of the neoadjuvant comparing the combination of the approved drugs abiraterone acetate and enzalutamide vs. abiraterone acetate combined with LHRHa in men with a high risk, localized disease. Dr Efstathiou explains that with all the new guidelines coming forth, even if these male patients get a prostatectomy, or even if they follow the approach of a combination of both radiation and LHRH for 2-3 years, there will be a very significant subset of these men who will relapse. She further explains that this trial addressed the unmet need set out above. She reflects on the talks last year, where the use of abiraterone plus LHRHa was suggested to be a good idea for new adjuvant treatment for these men given that it induces hydroreduction. Now, researchers are looking for an even better readout with a combination. She proceeds to explain that the abiraterone with LHRHs combination worked better than the 3-drug combination. At that point, the question asked was ‘Was there a drug-drug interaction?’. However, there was no indication of this. Following this, she explains that markers were then studied. In the 3-drug combination, more of the potential markers for primary resistance were found. Finally, all the cancers that seemed to be resisting the treatment were then studied; this analysis showed that there was an association with phosphatase and tensin homolog (PTEN) loss that had also been reported pre-clinically. This trial therefore proved to be very informative in finding out what is happening at the tumor micro-environment level. Recorded at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Views: 209 VJOncology
Casodex works well in prostate cancer
 
01:58
http://goo.gl/McmYWg
Dr. Concepcion on The Use of Eligard in Prostate Cancer Treatment
 
02:28
Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.
Views: 648 OncLiveTV
How To Prepare Leuprolide Acetate Injection?
 
02:09
Many of doctors or nurses do not know how to prepare Leuprolide acetate injection, so we have filmed this video tutorial so that you can understand it better. The procedure seems to be quite complicated, but it is very simple. But you must take during attaching needle, otherwise material may ooze out due to negative pressure.
Views: 38223 Dr. Vikram
Day 1 on Lupron Depot.
 
01:06
Just doing a video blog on lupron. Treatment for endometriosis. This medication is testosterone.
Views: 1112 Megan
Hormonal Therapy for Prostate Cancer
 
22:00
A discussion of hormonal therapy for prostate cancer patients considering their treatment options
Views: 26288 CancerClinicalTrials
Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix or Leuprolide
 
02:42
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
Views: 112 OncLiveTV
Abiraterone Acetate for Prostate Cancer
 
02:31
Dr. Matthew Cooney reviews how abiraterone acetate is used for the treatment of advanced prostate cancer. He discusses how to limit the side effects and what to consider once it stops working. http://prostatecancerletter.com/
Views: 2163 Matthew Cooney
Androgen deprivation therapy for prostate cancer
 
01:19
Today, CancerBro will explain what is prostate cancer deprivation therapy. Video Transcript: The next treatment modality is androgen deprivation therapy. For this, we first have to understand the hormonal axis causing the testosterone release. Pituary gland releases LH and FSH, which directly acts on the testis to release testosterone. ACTH released from pituitary gland acts on the adrenal gland to release DHEA, which subsequently gets converted into testosterone. The testosterone released from testis and adrenal gland enters the prostate cell and gets converted into DHT which causes the growth and survival of prostate cancer cells. We can block this pathway, to reduce the action of testosterone on prostate cancer cells. GNRH agonists or antagonists prevents the release of LH, FSH and ACTH from pituitary gland. Then come the cytochrome 17P inhibitors that prevent the release of testosterone from testis and adrenal gland. And finally there are androgen receptor blockers that prevents the binding of testosterone to prostate cancer cells, thereby preventing it's action. Another method for androgen deprivation is surgical castration in which both testes are removed. Unlike medical constration it is a one time procedure. CancerBro is also active on most social media channels. Follow him to get rich and authoritative content related to cancer awareness, risk factors, symptoms, diagnosis, treatment, etc. Facebook - https://www.facebook.com/officialcancerbro/ Instagram - https://www.instagram.com/official_cancerbro/ Twitter - https://twitter.com/cancer_bro/ Website - http://www.cancerbro.com/
Views: 45 CancerBro
Can Advanced Prostate Cancer Be Cured?
 
41:10
http://www.balancedhealthtoday.com http://www.balancedhealthtoday.com/endosterol.html Currently, no cure exists for advanced prostate cancer. Men can benefit, however, in several ways. Some treatments slow the growth of the cancer. Others reduce symptoms caused by the disease. Until recently, no therapy was offered to prolong life. However, the recently approved chemotherapy drug Taxotere, when taken with the steroid prednisone, has been proven to extend survival by several months. Taxotere is approved only for men with cancer that no longer responds to hormone therapy (called hormone refractory prostate cancer). In addition, Provenge, a "vaccine" for the treatment of advanced prostate cancer, does appear to extend survival -- by months for most patients, by years for some. Provenge isn't your everyday vaccine. It's an immune therapy created by harvesting immune cells from a patient, genetically engineering them to fight prostate cancer, and then infusing them back into the patient. It's approved only for treatment of patients with few or no symptoms who have prostate cancer that has spread outside the prostate and no longer responds to hormone therapy. http://www.balancedhealthtoday.com/store http://www.balancedhealthtoday.com/store/endosterol.html
Views: 161 Martina Santiago
MEDICAMENTO PROSTATA
 
01:35
El cáncer de Próstata ya puede ser tratado en Panamá, con un nuevo medicamento que fue presentado por la compañía Asofarma Centroamérica. Se trata de Eligard (Acetato de Leuprolide), que fue presentado al mercado y especialistas Panamá. Es un análogo de la hormona liberadora de luteinizantes utilizado para producir una castración química, inhibiendo la síntesis de testosterona.
Views: 5192 webestoestour
Research news: Advanced prostate cancer drug Abiraterone approved by NICE
 
01:22
Prostate Action Chief Executive Emma Malcolm reacts to the decision by NHS rationing body NICE to approve the use of a life-extending drug for men suffering advanced symptoms of prostate cancer.
Views: 373 ProstateAction
Prostate Cancer Hormone Therapy | Memorial Sloan Kettering
 
04:52
Learn more about our cancer treatments here: http://www.mskcc.org/morescience Like us on Facebook: http://www.facebook.com/sloankettering Follow us on Twitter: http://twitter.com/sloan_kettering Widespread screening for prostate cancer means that men are now often diagnosed with the disease before it is detectable by digital-rectal exam. This means that doctors are treating a different, earlier-stage disease than they were 10 years ago, Memorial Sloan Kettering Cancer Center specialists say. For this reason the results of all treatment approaches are better in today's patients. {partial transcript} In other words, the studies and the numbers that we’ve seen, the patients themselves have selected which direction they want to go (that may introduce a little bias into the numbers). But we have thousands and thousands of cases that give us an idea. It shows that we’re looking at, generally, a ten to fifteen year survival rate. As we follow this out and I guess part of the difficulty is that prostate cancer is pretty slow growing. So we have to follow these men for a very long period of time before we start seeing a difference between radiation therapy and surgery. It’s hard to make a career in the natural history of prostate cancer because it basically takes your career. You take someone with a localized prostate cancer and you want to see if they are going to die of prostate cancer, you’ll need to follow them for twenty to twenty-five years. We have used intermediate end points and different ways of assessment and have found that just because someone has a recurrence of prostate cancer after a typical radiation, some times surgery… I’m just joking, it’s not a death sentence, and they do not all behave the same way. Their life expectancy is still measured in many years and they may not all behave on as if they’re going to have a rapid course.
Link Discovered Between Hormone Therapy for Prostate Cancer and Depression
 
00:51
A new study suggests older men who receive testosterone-suppressing therapy for prostate cancer may be at increased risk of developing depression. The findings are based on a large study of 78,000 U.S. men treated for earlier-stage prostate cancer. Researchers found that among those given hormone-suppressing therapy, 7 percent developed clinical depression in the next few years. 5 percent of men who did not have the treatment also developed depression. The findings do not prove that hormone therapy is to blame. However, senior researcher Dr. Paul Nguyen of Brigham and Women's Hospital in Boston says they do offer "pretty strong evidence" that might be the case. Nguyen said his team accounted for some other factors that could affect depression risk -- including the severity of a man's cancer, his age and education. And there was still a connection between hormone therapy and depression. Also, the longer the men were on hormone therapy, the higher the risk of depression. http://www.upi.com/Health_News/2016/04/11/Hormone-therapy-for-prostate-cancer-tied-to-depression/9031460418049/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Views: 269 Wochit News
Leuprolide
 
01:13
Views: 957 lrbrown05
Dr. Koontz Discusses LHRH in High-Risk Prostate Cancer
 
01:40
Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses a phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.
Views: 37 OncLiveTV
Lupron side effects
 
02:36
Lupron update.
Views: 1047 Suzanne Lewis
LHRH Agonists and Antagonists in Prostate Cancer
 
02:00
Carl Olsson, MD, compared the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer. Tune in here.
Views: 55 AUCOFNY1
Part 1- Darcy Spears News Report on Lupron Depot -  (KTVN, Las Vegas)
 
06:16
Darcy Spears News Report on Lupron Depot
Views: 10415 bettyjones22
TERRAIN: Enzalutamide versus bicalutamide for metastatic prostate cancer
 
01:30
Neal Shore, MD, FACS, from Atlantic Urology Clinics, Myrtle Beach, SC, discusses the results of the randomized, double-blind, phase 2 TERRAIN trial, which compared enzalutamide, a novel androgen receptor signalling inhibitor, with bicalutamide, a non-steroidal anti-androgen, for the treatment of men with metastatic castrate-resistant prostate cancer. Recorded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting,
Views: 325 Cancer ASEA
Lupron Depot Side Effects - Physical Symptoms (and House Hunt)
 
14:22
An update on my symptoms post Lupron Depot injection and other things. Insta: instagram.com/liv4todayvlog Facebook: https://www.facebook.com/liv4todayvlog/ blog: femmeinfertile.blogspot.com Music: http://www.bensound.com/royalty-free-music
Views: 3172 Liv 4 Today
NICE decision to reject prostate cancer drug Abiraterone
 
02:46
Prostate Action CEO Emma Malcolm discusses the decision from NICE to reject Abiraterone for use by the NHS, a drug used to treat advanced prostate cancer.
Views: 583 ProstateAction
Dr. Morgan on Enrolling Patients With Prostate Cancer onto Clinical Trials
 
01:32
Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.
Views: 57 OncLiveTV
Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer
 
01:22
Abiraterone Information visit: http://www.abiraterone.org Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer sperm fertility surgery varicoceles prostate cancer drug tumor salt sodium obesity blood pressure heart attack stroke treatment abiraterone acetate hormone therapy Abiraterone research
Views: 1350 Music2088
Nurse Linda IVF Medication Injections - Lupron
 
05:27
Nurse Linda of the Sher Institute for Reproductive Medicine (SIRM) demonstrates the process for preparing and injecting Lupron for your IVF cycle. Learn more at http://www.haveababy.com
Leuprolide Acetate Injection (Lupron)
 
01:14
Leuprolide Acetate (Lupron) is related to a naturally occurring hormone called gonadotropin releasing hormone (GnRH). Leuprolide Acetate has also been used to treat endometriosis, uterine fibroids, early puberty, and as part of the process to stimulate multiple eggs for assisted reproductive technologies. The strength of Leuprolide Acetate is 1mg/0.2ml. Leuprolide Acetate is administered as a subcutaneous injection using insulin syringes. Insulin syringes are used because the measurement on the syringe is in units (i.e.: 10 units is equivalent to 0.1ml/cc). For the role it plays in assisted reproductive technologies, Leuprolide Acetate is used to reduce the amount of estrogen and testosterone in the body. This decrease in estrogen production will prevent ovulation and stop menstrual periods. For questions regarding medication administration or to speak to our nurse or pharmacist, please call 877-334-1610.
Views: 70114 Village Pharmacy
What Types Of Hormone Therapy Are Used For Prostate Cancer?
 
41:10
http://www.balancedhealthtoday.com http://www.balancedhealthtoday.com/endosterol.html Hormone therapy for prostate cancer—also called androgen suppression therapy or androgen deprivation therapy—can block the production and use of androgens (3). Currently available treatments can: Reduce androgen production by the testicles Block the action of androgens in the body Block the production of androgens throughout the body http://www.balancedhealthtoday.com/store http://www.balancedhealthtoday.com/store/endosterol.html
Views: 74 Martina Santiago
Prostate Cancer Case-study
 
04:08
Learn how to breakdown a clients health history to develop a safe and effective exercise program for a prostate cancer patient.
Views: 36 Cancer Exercise
Leuprolide Acetate Injection
 
03:31
Demonstration of administering a Leuprolide Acetate injection Washington University Fertility and Reproductive Medicine Center https://fertility.wustl.edu 314-286-2400 Central West End: 4444 Forest Park Ave., Suite 3100, St. Louis, MO 63110 Missouri Baptist Medical Center: 3023 N. Ballas Rd., Building D, Suite 450, St. Louis, MO 63131